直覺手術 (ISRG) 2002 Q2 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Good afternoon, and welcome to the Intuitive Surgical second quarter earnings release conference call. All participants will be able to listen-only until the question-and-answer session of the call. This conference is being recorded.

    各位下午好,歡迎參加直覺外科(Intuitive Surgical)第二季財報發布電話會議。在本次電話會議的問答環節開始之前,所有與會者將僅能收聽。本次會議將被錄音。

  • I would like to introduce your first speaker for today?s call, Mr. Ben Gong, Vice President, Treasurer, and Corporate Controller. Sir, you may begin.

    我想為各位介紹今天電話會議的第一位講者:Ben Gong 先生,副總裁、財務長(Treasurer)暨公司財務控管長(Corporate Controller)。先生,您可以開始了。

  • Ben Gong

    Ben Gong

  • Good afternoon. And welcome to Intuitive Surgical?s second quarter conference call. With me today we have Lonnie Smith, our President and CEO, Susan Barnes, our Chief Financial Officer, Fred Moll, our Co-Founder and Medical Director, Alex [Sutkege], our Vice President of Business Development and Strategic Planning, and David Shaw, our Vice President of Legal Affairs and Corporate Counsel.

    各位下午好。歡迎參加直覺外科第二季電話會議。今天與我一同出席的有:我們的總裁兼執行長 Lonnie Smith、財務長 Susan Barnes、共同創辦人兼醫務總監 Fred Moll、副總裁(業務發展與策略規劃)Alex [Sutkege],以及法務副總裁兼公司法律顧問 David Shaw。

  • Before we begin, I would like to inform you that comments mentioned on today?s call may be deemed to contain forward-looking statements. Actual results may differ materially from those expressed or implied as a result of certain risks and uncertainties. These risks and uncertainties are described in detail in the company?s Securities & Exchange Commission filings. Prospective investors are cautioned not to place undue reliance on such forward-looking statements.

    在開始之前,我想提醒各位,今天電話會議中提及的評論可能被視為包含前瞻性陳述。由於若干風險與不確定性,實際結果可能與明示或暗示的內容有重大差異。這些風險與不確定性已在本公司向美國證券交易委員會(SEC)提交的文件中有詳細說明。提醒潛在投資人切勿過度依賴此類前瞻性陳述。

  • Please note that this conference call will be available for audio replay on our web site at www.intuitivesurgical.com on the audio archive section under our Investor Relations page. In addition, today?s press release has been posted to our web site.

    請注意,本次電話會議的錄音重播將可於我們網站 www.intuitivesurgical.com 的「投資人關係」頁面下之音訊存檔區收聽。此外,今天的新聞稿也已發布於我們的網站。

  • Today?s format will consist of providing you with highlights of the second quarter, as described in our press release announced earlier today, followed by a question-and-answer session. First, Lonnie will present the business highlights of the second quarter. Susan will follow with a review or a second quarter?s financial results and provide an outlook for the third quarter. Next, Fred, will describe our most recent clinical and regulatory progress. Alex will discuss sales and marketing. And then David will update you regarding intellectual property issues, including further details on today?s press release. Finally, we will host a question-and-answer session.

    今天的流程將先提供第二季重點摘要(如同我們稍早發布的新聞稿所述),接著進行問答環節。首先,Lonnie 將說明第二季的業務重點。接著 Susan 將回顧第二季財務結果,並提供第三季展望。然後 Fred 將說明我們最新的臨床與法規進展。Alex 將討論銷售與行銷。接著 David 將就智慧財產權議題提供最新進度,包括今天新聞稿的進一步細節。最後,我們將進行問答環節。

  • With that, I would like to introduce Lonnie Smith, our President and CEO.

    接下來,我想介紹我們的總裁兼執行長 Lonnie Smith。

  • Lonnie Smith

    Lonnie Smith

  • Thank you, Ben.

    謝謝你,Ben。

  • I?d like to thank each of you for taking the time to join us for today?s conference call. We will begin with a review of the highlights of the second quarter. We had strong second quarter financial results. We shipped 16 da Vinci Surgical Systems, and ended the quarter with 118 systems installed worldwide, achieved record revenue of 19.4 million up 52 percent from prior year, grew recurring revenue to 3.3 million up 82 percent from prior year, and grew gross margin to 52 percent. We used only a little over one million in cash, ending the quarter with 55.4 million in cash and cash equivalents.

    感謝各位撥冗參加今天的電話會議。我們將先回顧第二季的重點摘要。我們第二季的財務表現強勁。我們出貨 16 套達文西(da Vinci)手術系統,並在季末使全球安裝量達到 118 套;營收創下 1,940 萬美元新高,較去年同期成長 52%;經常性收入成長至 330 萬美元,較去年同期成長 82%;毛利率提升至 52%。我們僅使用略高於 100 萬美元的現金,季末現金及約當現金為 5,540 萬美元。

  • We?re quite pleased with our revenue growth, improving gross margins, and cash management in the second quarter. We continue to see healthy growth in our recurring revenue stream, and increased system usage. Susan will provide further financial details later in this call.

    我們對第二季的營收成長、毛利率改善以及現金管理感到相當滿意。我們持續看到經常性收入來源的健康成長,以及系統使用量的提升。Susan 稍後將在本次電話會議中提供更進一步的財務細節。

  • Approximately two-thirds of the systems shipped in the second quarter went to community hospitals. We completed our U.S. clinical trial for mitral valve repair, and will submit the results to the FDA shortly. We completed our clinical trial for [General Shonen] approval in Japan. We received [C-mark] clearance to market in Europe our endoscopic heart stabilizer for beating heart coronary bypass. And this morning we received the favorable rulings from the Delaware Court. Those rulings are detailed in a press release issued earlier today, and we will proceed to trial in two weeks.

    第二季出貨的系統中,約三分之二交付給社區醫院。我們已完成二尖瓣修補的美國臨床試驗,並將很快把結果提交給 FDA。我們已完成在日本取得 [General Shonen] 核准的臨床試驗。我們已取得歐洲的 [C-mark] 核准,可行銷用於跳動心冠狀動脈繞道手術的內視鏡心臟穩定器。而且今天早上,我們收到了德拉瓦州法院的有利裁定。這些裁定已在今天稍早發布的新聞稿中詳述,我們將在兩週後進入審判程序。

  • As we?ve mentioned in last quarter?s call we moved to a new 83,000 square foot facility in last February. We?ve now been up and running in this new facility for approximately five months, and we couldn?t be more pleased. It has proven to be a true asset to the company, contributing to the productivity of our employees, and creating a positive impression for all who visit. Our expanded lab facilities, combined with our customer demonstration and training center, have greatly enhanced our clinical development and our customer education capabilities.

    如同我們在上一季電話會議中提到的,我們於去年二月搬遷至一座新的 83,000 平方英尺廠房。我們在這座新廠房運作至今約五個月,對此再滿意不過。它已證明是公司的重要資產,有助於提升員工生產力,並為所有來訪者留下正面印象。我們擴充的實驗室設施,結合客戶示範與訓練中心,大幅提升了我們的臨床開發與客戶教育能力。

  • The new mobile operating room and demonstration system we introduced last quarter has been a great success. As you may remember this is an 85-foot tractor trailer that expands accordion-style to a full operating room, which allows us to easily take surgical demonstrations of the da Vinci System to medical centers across the United States. During the quarter this mobile system was completely booked, and competition among our sales force for use of this system was very intense. The power of this tool beyond its visibility is that it can significantly shorten the selling cycle by making it possible for surgeons or staff, hospital administrators, to see and test-drive the system in a single day without disruption to their schedules. On-site system demonstrations clearly accelerated the purchase process at several hospitals this past quarter.

    我們在上一季推出的新型行動手術室與示範系統非常成功。各位或許記得,這是一台 85 英尺的拖車式卡車,可像手風琴般展開成完整手術室,使我們能輕鬆將達文西系統的手術示範帶到全美各地的醫療中心。本季期間,這套行動系統的檔期完全排滿,我們的銷售團隊對其使用權競爭非常激烈。此工具除了能見度之外的威力在於:它能顯著縮短銷售週期,讓外科醫師或工作人員、醫院管理者能在不影響行程的情況下,於一天內完成觀看與試用系統。過去一季,在院內進行的系統示範,明顯加速了數家醫院的採購流程。

  • We?ve now received the results of a recently completed JD Power study for survey of our customers. This is a comprehensive survey covering all aspects of our business. The purpose of the survey is to obtain objective third-party feedback on our performance in the eyes of our customers, to help us to prioritize and focus our efforts to better serve them.

    我們已收到近期完成的 JD Power 客戶調查研究結果。這是一項涵蓋我們業務各層面的全面性調查。該調查的目的,是取得客觀的第三方回饋,了解客戶眼中我們的表現,並協助我們排定優先順序、聚焦資源,以更好地服務客戶。

  • Overall, the results demonstrated that our customers are quite happy with their purchase of the da Vinci System. When asked the question if they believed that their hospital had made a good decision to buy the da Vinci Surgical System, physicians gave us an average rating of nine on a scale of one to 10. Their survey also indicated they are quite pleased with the surgical capabilities of the da Vinci System, and are enthusiastic about increasing its use in their practices.

    整體而言,結果顯示我們的客戶對購買達文西系統相當滿意。當被問到是否認為其醫院購買達文西手術系統是正確決策時,醫師在 1 到 10 分的量表上給了我們平均 9 分的評價。調查也顯示,他們對達文西系統的手術能力相當滿意,並對在其臨床實務中增加使用量感到非常期待。

  • On the legal front our joint Delaware litigation with IBM against Computer Motion is set to begin in early August. And in California we?ve begun filing our summary judgment motions. David Shaw will give you the details later in this call.

    在法務方面,我們與 IBM 共同在德拉瓦州對 Computer Motion 提起的訴訟,預計將於八月初開庭。在加州方面,我們已開始提出簡易判決(summary judgment)動議。David Shaw 稍後將在本次電話會議中提供細節。

  • With that, I?ll pass the time over to Susan who will discuss our second quarter financial results.

    接下來,我把時間交給 Susan,由她說明我們第二季的財務結果。

  • Susan Barnes

    Susan Barnes

  • Thank you, Lonnie.

    謝謝你,Lonnie。

  • Overall, as Lonnie mentioned earlier we had a strong second quarter with our financial performance meeting or exceeding our established goals. We realized 19.4 million of revenue which exceeded our previous record of 16 million by over $3 million. We improved gross margin to 52 percent which represented our first quarter over 50 percent, and exceeded our previous quarter by over three percent. We recorded a net loss of 10 cents per share, while using only $1.2 million in cash.

    整體而言,如同 Lonnie 先前提到的,我們第二季表現強勁,財務績效達到或超越既定目標。我們實現營收 1,940 萬美元,較先前 1,600 萬美元的紀錄高出逾 300 萬美元。我們將毛利率提升至 52%,這是我們首次單季超過 50%,並較上一季提高逾 3 個百分點。我們每股淨損 0.10 美元,同時僅使用 120 萬美元現金。

  • Our second quarter 2002 revenue was $19.4 million, up 52 percent from second quarter 2001 revenue of 12.7 million. We shipped 16 da Vinci Surgical Systems during the quarter, 13 in the United States, and three in Europe. The 16 total units shipped, were up four compared to 12 units shipped during the second quarter of 2001. We now have cumulative placements of 118 systems. 75 in the United States, 38 in Europe, and five in the rest of the world.

    我們 2002 年第二季營收為 1,940 萬美元,較 2001 年第二季的 1,270 萬美元成長 52%。本季出貨 16 套達文西手術系統,其中美國 13 套、歐洲 3 套。本季出貨總量 16 套,較 2001 年第二季出貨 12 套增加 4 套。我們目前累計安裝 118 套系統:美國 75 套、歐洲 38 套、世界其他地區 5 套。

  • Total Q2 2002 revenues by product group was as follows: systems 15.6 million, instrument and accessories 2.7 million; and service 1.1 million. Included in the instrument and accessory category is $500,000 related to the sales of a separate surgeon console to one of our existing customers. Excluding the impact of this specific item the current revenue was up 82 percent compared to Q2 2001.

    2002 年第二季按產品組別劃分的總營收如下:系統 1,560 萬美元;器械與配件 270 萬美元;服務 110 萬美元。器械與配件類別中包含 50 萬美元,係向我們一位既有客戶銷售一套獨立的外科醫師控制台所致。若排除此特定項目的影響,經常性收入較 2001 年第二季成長 82%。

  • Recurring revenue grew to 3.3 million or 17 percent of total revenue, compared to 1.8 million or 14 percent of revenue in the second quarter of 2001. Our recurring revenue continues to climb each quarter as we place more systems, and our customers perform more robotic procedures.

    經常性收入成長至 330 萬美元,占總營收 17%;相較之下,2001 年第二季為 180 萬美元,占營收 14%。隨著我們安裝更多系統,且客戶執行更多機器人手術,我們的經常性收入將持續逐季攀升。

  • Total year-to-date sales equaled 33.8 million, up nine million or 36 percent compared to the first half of 2001.

    截至今年迄今的總銷售額為3,380萬,較2001年上半年增加900萬或36%。

  • Second quarter 2002 gross margins rose to 52 percent, compared to 48 in the same quarter last year. The improvement in gross margin over the prior year resulted in large part from a higher da Vinci Surgical System average selling price and higher unit sales.

    2002年第二季毛利率上升至52%,相較去年同季為48%。毛利率較去年改善,主要來自達文西手術系統(da Vinci Surgical System)平均售價提高以及銷售台數增加。

  • Total operating expenses for the second quarter of 2002 were 14.4 million, up 3.4 million compared to the second quarter of 2001. Our operating expense for the quarter was higher than we had guided. This was primarily due to a spike in R&D expenses related to new product development.

    2002年第二季營業費用總額為1,440萬,較2001年第二季增加340萬。本季營業費用高於我們先前的指引。主要原因是與新產品開發相關的研發費用短期大幅上升。

  • Research and development expense was 4.6 million in the second quarter of 2002, of approximately 1.3 million from the 3.3 million in the second quarter last year. This increased versus prior year, resulted from headcount growth and higher prototype material costs.

    2002年第二季研發費用為460萬,較去年第二季的330萬增加約130萬。相較去年增加,係因人員編制擴增以及原型機材料成本上升所致。

  • SG&A expenses were $9.8 million in the second quarter of 2002, up approximately 2.1 million from the 7.7 million in the second quarter 2001. The increase over prior year was mainly due to growth in our field sales and support organization.

    2002年第二季銷售、一般及行政(SG&A)費用為980萬,較2001年第二季的770萬增加約210萬。較去年增加主要是因我們的外勤銷售與支援組織擴張。

  • Non-cash deferred compensation and patent amortization expenses represented 400,000 of total operating expenses in Q2 2002, compared to $770,000 in Q2 2001.

    2002年第二季非現金遞延薪酬及專利攤銷費用占營業費用總額40萬美元,相較2001年第二季為77萬美元。

  • We ended the quarter with 272 regular employees, up 15 from the previous quarter end. Total worldwide field employees increased by four, from 65 to 69 during the quarter. The remainder of the additions were primarily in manufacturing and engineering.

    本季期末我們共有272名正式員工,較前一季期末增加15人。全球外勤員工本季增加4人,由65人增至69人。其餘新增人力主要配置於製造與工程部門。

  • Other income was approximately $500,000 for Q2 2002, compared to a $700,000 income in the second quarter of 2001. The decrease is mainly due to lower cash balances and lower rates of return off earned on cash investments.

    2002年第二季其他收益約為50萬美元,相較2001年第二季收益為70萬美元。下降主要因現金餘額較低,以及現金投資的報酬率較低。

  • Our net loss for the second quarter 2002 was $3.7 million or 10 cents per share, compared to 4.2 million or 12 cents per share in the second quarter of 2001.

    2002年第二季淨損為370萬美元或每股10美分,相較2001年第二季為420萬美元或每股12美分。

  • Basic and diluted shares outstanding for EPS calculations were 36.4 million shares for the second quarter of 2002, compared to 35.7 million shares for the same period last year.

    用於每股盈餘(EPS)計算的基本及稀釋後流通在外股數,2002年第二季為3,640萬股,相較去年同期為3,570萬股。

  • Now, in regards to our balance sheet. We ended the quarter with $55.4 million in cash, down 1.2 million from the previous quarter end. The reduction reflected the company?s net loss of 3.7 million, offset by non-cash expenses of 1.1 million and favorable working capital changes.

    接下來談資產負債表。本季期末現金為5,540萬美元,較前一季期末減少120萬美元。減少反映公司淨損370萬美元,部分由110萬美元的非現金費用及有利的營運資金變動所抵銷。

  • Our quarter end accounts receivable balance of $15.2 million was down 300,000 from the previous quarter end. Taking into account our higher Q2 revenue, our average day sales outstanding was 71 days, down from 97 at the end of Q1.

    本季期末應收帳款餘額為1,520萬美元,較前一季期末減少30萬美元。考量第二季營收較高,我們的平均應收帳款週轉天數為71天,較第一季期末的97天下降。

  • Ending fourth quarter net inventory was at 7.2 million, up about $1 million from the previous quarter end, reflecting higher sales volume. Our annual inventory turns are now about 5.1, compared to the 4.8 we had at the end of the first quarter.

    第四季期末淨存貨為720萬美元,較前一季期末增加約100萬美元,反映銷售量提高。我們的年度存貨週轉率目前約為5.1,較第一季期末的4.8提升。

  • In regards to our outlook for the third quarter we expect third quarter revenues to come in between $15 and $19 million on system unit shipments of between 12 and 16 systems. The third quarter tends to be our slowest due to the impact of summer vacation season in Europe and the United States. We anticipate Q3 gross margins to decrease slightly due to lower sales and production volume.

    關於第三季展望,我們預期第三季營收介於1,500萬至1,900萬美元,系統出貨量介於12至16套。由於歐洲與美國暑期休假季的影響,第三季通常是我們最淡的一季。我們預期第三季毛利率將因銷售與生產量較低而小幅下降。

  • We expect operating expenses in the third quarter to be equal to or slightly lower than the second quarter. Due to, including expenses related to several trade shows with only one to occur in Q3. We also had high prototype expenses in Q2. We don?t expect these expenses to be at the same level moving forward. Offsetting these items we do plan to grow our sales force and customer field support organizations, and to incur more legal expenses as our trial gets computer motion and begins in Delaware.

    我們預期第三季營業費用將與第二季相當或略低。原因包括:與多場商展相關的費用,其中僅有一場會在第三季舉行。此外,第二季原型機費用偏高。我們預期未來這些費用不會維持在相同水準。抵銷上述因素的是,我們計畫擴增銷售團隊與客戶外勤支援組織,並且隨著我們與 Computer Motion 的訴訟在德拉瓦州開庭,將產生更多法律費用。

  • We expect the average number of shares outstanding during the third quarter of 2002 for EPS calculations to be approximately 36.6 million shares.

    我們預期2002年第三季用於EPS計算的平均流通在外股數約為3,660萬股。

  • And with that, I?d like to turn it over to Fred who will provide a summary of our latest clinical progress.

    接下來,我想把時間交給Fred,由他為大家總結我們最新的臨床進展。

  • Frederic Moll

    Frederic Moll

  • Thanks, Susan.

    謝謝你,Susan。

  • I am pleased to report that we have made significant progress in our cardiac clinical trials, product offerings, and surgical procedures. As Lonnie highlighted earlier, we have completed all cases required to file a 510-K for mitral valve repair. And we expect to file this application within the next few days. We are confident in the quality of the data and anticipate clearance by the end of this year. Importantly, the FDA has granted permission for all sits involved in the mitral trial to continue performing this procedure while the agency is reviewing our application.

    我很高興報告,我們在心臟臨床試驗、產品供應,以及手術流程方面都取得顯著進展。如同Lonnie先前強調的,我們已完成提交二尖瓣修補(mitral valve repair)510-K所需的所有病例。我們預期在接下來幾天內提出此申請。我們對資料品質充滿信心,並預期在今年底前取得核准。重要的是,FDA已允許所有參與二尖瓣試驗的醫療據點在主管機關審查我們申請期間,仍可持續執行此手術。

  • Cases for the atrial septal defector [para] trial are progressing positively, and we expect to file our 510-K during the fourth quarter and receive FDA clearance for this syndication by the first quarter of next year.

    心房中隔缺損(atrial septal defector [para])試驗的病例進展良好,我們預期將於第四季提交510-K,並在明年第一季前取得FDA對此適應症的核准。

  • Our coronary artery bypass trial is also progressing with cases ongoing. We believe we are still on-pace to obtain [cavedge] clearance by the end of 2003.

    我們的冠狀動脈繞道手術試驗也在推進中,病例持續進行。我們相信仍按進度可在2003年底前取得 [cavedge] 核准。

  • During the second quarter we received CE mark clearance to market our new heart stabilizer product, key to the execution of beating heart cavedge procedures. We will introduce the new beating heart system to all of our European customers next month. The beating heart cavedge procedure continues to improve with clinical investigators now achieving consistent three-hour case times and highly reproducible results.

    第二季期間,我們取得CE標誌核准,可行銷我們新的心臟穩定器產品,該產品是執行跳動心臟 [cavedge] 手術的關鍵。我們將於下個月向所有歐洲客戶推出新的跳動心臟系統。跳動心臟 [cavedge] 手術持續改善,臨床研究者目前已能穩定達成三小時手術時間,且結果高度可重複。

  • In neurology we have had another quarter of strong growth in the da Vinci prostatectomy, or DVP procedure. The number of DVPs performed in Q2 grew by over 25 percent versus Q1. Also, the number of sites performing the DVP grew by 35 percent versus Q1. We are seeing patient demand driving this procedure, and regional competition intensifying.

    在神經領域,我們在達文西前列腺切除術(da Vinci prostatectomy,DVP)方面再度迎來強勁成長的一季。第二季執行的DVP數量較第一季成長超過25%。此外,執行DVP的醫療據點數較第一季增加35%。我們看到病患需求推動此手術,同時區域競爭也在加劇。

  • Regarding new procedures we are excited about the expanding role of the da Vinci System in microsurgical applications. The ability of da Vinci to provide precise, articulated movement under high magnification offers a unique clinical capability in microsurgical technique.

    就新手術而言,我們對達文西系統在顯微外科應用中日益擴大的角色感到振奮。達文西能在高倍率放大下提供精準、可關節式的動作,為顯微外科技術帶來獨特的臨床能力。

  • For example, recently Dr. Richard Graham at the [Marenko] Doctors Hospital in Richmond, Virginia was the first to perform a microsurgical vasectomy reversal by using the Intuitive System. Other procedures in the area of plastic, reconstructive, and vascular surgery are ideal candidates to robotic technique. We see many of these procedures being done in the future as microsurgeons discover the capabilities of Intuitive?s technology.

    例如,近期維吉尼亞州里奇蒙的 [Marenko] Doctors Hospital 的Richard Graham醫師,首次使用Intuitive系統完成顯微輸精管結紮逆轉手術。在整形、重建與血管外科領域的其他手術,也非常適合採用機器人技術。我們預期,隨著顯微外科醫師逐步發掘Intuitive技術的能力,未來將有更多此類手術得以執行。

  • That completes my summary, and I?ll pass the time over to Aleks Cukic.

    以上是我的摘要,接下來把時間交給Aleks Cukic。

  • Aleks Cukic

    Aleks Cukic

  • Thank you, Fred.

    謝謝你,Fred。

  • As was previously mentioned we shipped 16 da Vinci Surgical Systems during the second quarter, the most in any quarter thus far for Intuitive. We had another strong quarter in the U.S. with 13 units going to U.S. customers. We again installed our systems in some of the most prestigious hospitals in the country, including New York University, The University of Pennsylvania, William Beaumont Hospital in Royal Oak, Michigan, St. Luke?s, Kansas City, and St. Joseph?s, Atlanta. Three systems were sold in Europe, up from one in the previous quarter.

    如先前所提,我們在第二季出貨16套達文西手術系統,為Intuitive迄今單季最高。我們在美國市場再度交出強勁表現,13套出貨給美國客戶。我們再次在全美一些最具聲望的醫院完成系統裝機,包括紐約大學(New York University)、賓夕法尼亞大學(The University of Pennsylvania)、密西根州Royal Oak的William Beaumont Hospital、堪薩斯市的St. Luke?s,以及亞特蘭大的St. Joseph?s。歐洲地區售出3套,高於前一季的1套。

  • We continue to see a higher percentage of systems shipped to community hospitals versus academic institutions. Five of our Q2 sales were to academic centers, while 10 went to community hospitals. The remaining system was sold directly to a physicians practice. The Peoria Surgical Group of Illinois became the first group of physicians to directly acquire da Vinci System as a strategic investment for their practice. The fact that these surgeons are willing to invest in a da Vinci Surgical System out of their own pockets for their own practice is a significant testimony as to the economic benefits that the da Vinci Surgical System offers.

    我們持續看到出貨至社區醫院的系統占比高於學術機構。第二季銷售中,有5套售予學術中心,10套售予社區醫院。其餘1套則直接售予醫師執業機構。伊利諾伊州的Peoria Surgical Group成為第一個以其執業策略性投資為目的、直接購置達文西系統的醫師團體。這些外科醫師願意自掏腰包為自己的執業投資達文西手術系統,充分證明達文西手術系統所帶來的經濟效益。

  • We were very active during the second quarter at various trade shows. In the cardio thoracic area we attended the American Association of Thoracic Surgeons meeting in Washington, D.C. Thoracic surgery has been an area of momentum for us, particularly in the Esophageal and lung surgeries.

    我們在第二季期間於各類貿易展會上非常活躍。在心胸外科領域,我們參加了於華盛頓特區舉行的美國胸腔外科醫師學會(American Association of Thoracic Surgeons)年會。胸腔外科一直是我們動能強勁的領域,特別是在食道與肺部手術方面。

  • In June we participated in the International Society of Minimally Invasive Cardiac Surgeons Conference in New York City. As Intuitive gets closer to obtaining U.S. cardiac clearances we have seen many U.S. hospitals show considerable clinical interest, as to have time to plan and implement their robotics programs around these clearances. This show generated a significant number of high-quality leads for Intuitive.

    6 月我們參加了在紐約市舉行的國際微創心臟外科醫師學會(International Society of Minimally Invasive Cardiac Surgeons)年會。隨著 Intuitive 越來越接近取得美國心臟手術相關許可,我們看到許多美國醫院展現出相當高的臨床興趣,並希望能有時間圍繞這些許可來規劃與導入其機器人手術計畫。本次展會為 Intuitive 帶來了大量高品質的潛在客戶線索。

  • Also in June we attended The American Society of [Bariatric] Surgeons meeting for the first time. Bariatric, or obesity surgery, is another area that we have experienced recent growth and see great potential to capitalize on the da Vinci?s strengths.

    同樣在 6 月,我們也首次參加了美國[減重]外科醫師學會(The American Society of [Bariatric] Surgeons)年會。減重(或肥胖)手術是我們近期成長的另一個領域,我們也看到很大的潛力可善用達文西(da Vinci)的優勢。

  • Several hospitals such as Mt. Sinai, New York, Westchester Medical Center, and the University of Illinois, Chicago have done a significant number of successful gastric bypasses and gastric banding procedures with the da Vinci Surgical System.

    多家醫院,例如紐約西奈山醫院(Mt. Sinai)、威徹斯特醫療中心(Westchester Medical Center)以及伊利諾大學芝加哥分校(University of Illinois, Chicago),已使用達文西手術系統成功完成大量胃繞道與胃束帶手術。

  • Our biggest marketing event of the quarter was probably the American Neurology Association Meeting held in Orlando. Overall attendance was close to 10,000, about equally split between international attendees and U.S. At this show there were eight different presentations highlighting Intuitive and the da Vinci Surgical System. One of the most impressive was that of Dr. Manny [Menan] of Henry Ford Hospital in Detroit, who presented his DBT technique and clinical results in a session attended by nearly a thousand neurologists.

    本季我們最大的行銷活動,可能是於奧蘭多舉行的美國神經學會(American Neurology Association)年會。整體出席人數接近 10,000 人,國際與美國與會者大致各半。在本次展會上,共有八場不同的發表聚焦於 Intuitive 與達文西手術系統。其中最令人印象深刻之一,是底特律亨利福特醫院(Henry Ford Hospital)的 Manny [Menan] 醫師,他在一場近千名神經科醫師出席的場次中,發表了其 DBT 技術與臨床成果。

  • Overall, this year?s AUA meeting was a key event for Intuitive Surgical. The quality of the leads and the enthusiasm were both very high. Surgeons are now both routinely seeing and hearing the successes that the da Vinci Surgical System brings to the field of urology. Those who attended our booth were very interested in becoming part of this robotic urology movement.

    整體而言,今年的 AUA 年會對 Intuitive Surgical 是一個關鍵活動。潛在客戶線索的品質與熱度都非常高。外科醫師如今已經能夠例行地看到並聽到達文西手術系統為泌尿科領域帶來的成功。參觀我們攤位的人都非常有興趣成為這股機器人泌尿科浪潮的一部分。

  • At this point, I?ll pass the time over to David Shaw who will discuss the legal developments of the quarter.

    接下來我把時間交給 David Shaw,由他說明本季的法律進展。

  • David Shaw

    David Shaw

  • Thanks, Alex.

    謝謝你,Alex。

  • I?ll first address our joint Delaware litigation with IBM against Computer Motion on our patent covering voice-controlled surgical robots. We issued a press release earlier today explaining in greater detail what I?m about to cover.

    我先談我們與 IBM 在德拉瓦州針對 Computer Motion 的聯合訴訟,該案涉及我們關於語音控制手術機器人的專利。我們今天稍早已發布新聞稿,更詳細說明我接下來要談的內容。

  • This morning?s ?LA [indiscernible]? announced the results of the parties summary judgment motions. On our motion for judgment the district court concludes that all of Computer Motion?s AESOP, Zeus, and [Home Ease] products literally infringed the 984 patent. And so, entered summary judgment against Computer Motion on that basis. Intuitive, thus, will not now have to prove infringement at trial. This is a great result for us.

    今天早上的「LA [聽不清]」公布了雙方就簡易判決(summary judgment)動議的裁定結果。就我們提出的判決動議,地方法院認定 Computer Motion 的 AESOP、Zeus 與 [Home Ease] 產品均構成對第 984 號專利的文字侵權(literally infringed)。因此,法院基於此對 Computer Motion 作出簡易判決。因此,Intuitive 現在不必在審判中再證明侵權。這對我們而言是非常好的結果。

  • We?re equally pleased that the court also denied all four of Computer Motion?s own request for summary judgment. The court first rejected Computer Motion?s request that the case be thrown-out on the basis of prosecution laches and instead, after denying our cross motion on that same issue they set the defense for trial.

    我們同樣很高興法院也駁回了 Computer Motion 自行提出的四項簡易判決請求。法院首先否決了 Computer Motion 以「審查遲延抗辯」(prosecution laches)為由要求撤案的請求;並且在駁回我們就同一議題提出的交叉動議後,將該抗辯列入審判審理。

  • The court also refused Computer Motion?s request that the 984 patent be invalidated for lack of enablement or for violation of the best mode requirement. And further rejected Computer Motion?s attack on our standing to sue. Instead, affirmatively ruling that Intuitive is entitled to defend its marketplace as the exclusive licensee of the 984 patent.

    法院也拒絕了 Computer Motion 以未充分揭露(lack of enablement)或違反最佳模式要求(best mode requirement)為由主張第 984 號專利無效的請求。並進一步駁回了 Computer Motion 對我們起訴資格(standing)的攻擊。相反地,法院明確認定 Intuitive 作為第 984 號專利的獨家被授權人(exclusive licensee),有權捍衛其市場。

  • As a result of the court?s rulings and the entry of judgment for the AESOP, Zeus, and Home Ease infringe, if Computer Motion cannot now prove at trial by clear and convincing evidence that the 984 patent is somehow invalid or unenforceable it will face liability for patent infringement. Trial is now less than two weeks away.

    基於法院的裁定以及就 AESOP、Zeus 與 Home Ease 侵權所作出的判決,如果 Computer Motion 無法在審判中以明確且令人信服的證據(clear and convincing evidence)證明第 984 號專利在某種程度上無效或不可執行(unenforceable),它將面臨專利侵權責任。審判距今已不到兩週。

  • I will next address our interference proceedings against Computer Motion in the U.S. patent office, all of which have now concluded. As you likely already know, of the three Computer Motion patents we challenged interference we won two outright. As a result, Intuitive gained the right to patent those two key inventions for itself, and Computer Motion lost its entire former AESOP 193 patent and all of its former Zeus 583 patent.

    接著我將說明我們在美國專利商標局對 Computer Motion 提起的干涉程序(interference proceedings),目前均已結案。各位可能已經知道,在我們就三件 Computer Motion 專利提起干涉挑戰中,我們有兩件完全勝訴。因此,Intuitive 取得了將這兩項關鍵發明申請為自身專利的權利,而 Computer Motion 則失去了其原 AESOP 193 號專利的全部權利,以及其原 Zeus 583 號專利的全部權利。

  • Just yesterday Computer Motion filed its appeal of these judgments in the Central District of California. I won?t comment further on the appeal process at this point until Computer Motion has made its intentions clear to the court.

    就在昨天,Computer Motion 已就這些判決向加州中區地方法院提出上訴。在 Computer Motion 向法院明確表達其意圖之前,我目前不再就上訴程序進一步評論。

  • In the third interference on Computer Motion?s 664 patent the Patent Office ended judgment against this, ruling that we cannot patent that third invention for ourselves. Nevertheless it was left open whether the 664 patent is, in fact, invalid as we?d argued.

    在第三件、涉及 Computer Motion 第 664 號專利的干涉案中,專利局作出對我們不利的終局判決,認定我們不能將第三項發明申請為自身專利。然而,是否如我們所主張的那樣,第 664 號專利實際上無效,仍未被排除、仍留有爭議空間。

  • In any event, since the 664 patent did survive the itnerferences, and since Computer Motion now discovered that patent during its original prosecution we made the 664 the subject of our first motion for summary judgment of non-infringement in the California litigation to which I?ll now turn.

    無論如何,由於第 664 號專利在干涉程序中得以存續,且 Computer Motion 現在主張其在原始審查過程中已揭露該專利,我們已將第 664 號專利作為我們在加州訴訟中提出的第一項「不侵權」簡易判決動議(summary judgment of non-infringement)的標的;接下來我就轉到該案。

  • And the ongoing litigation against Computer Motion in California in which Computer Motion is attempting to assert its eight remaining patents against us, Intuitive has already filed four motions for summary judgment of non-infringement. We expect decisions on these four motions to start issuing sometime in the next several months.

    至於在加州對 Computer Motion 的持續訴訟中,Computer Motion 試圖以其剩餘的八件專利對我們主張權利,而 Intuitive 已提出四項不侵權的簡易判決動議。我們預期法院將在未來幾個月內陸續就這四項動議作出裁定。

  • We continue to believe in our ability to effectively defend on the merits all of Computer Motion?s remaining allegations, and look forward to the Court?s decisions on our first four motions. We anticipate filing further motions for summary judgement before year-end after the Court has addressed those already on file.

    我們仍然相信自己有能力就 Computer Motion 其餘所有主張在實體上有效抗辯,並期待法院就我們前四項動議作出裁定。在法院處理完目前已提出的動議後,我們預期在年底前還會提出進一步的簡易判決動議。

  • Finally, turning to our opposition proceeding and the European Patent Office against Computer Motion?s only European patent. Computer Motion previously announced in its April 3, 2002 press release that a preliminary ruling in this proceeding was in its favor. That is no longer accurate. On July 2nd the three-judge panel of the European Patent Office postponed consideration of the substantive issues in the opposition proceeding until after further written briefing can be submitted, thereby mooting the initial preliminary decision.

    最後,談到我們在歐洲專利局(European Patent Office, EPO)對 Computer Motion 唯一一件歐洲專利所提起的異議程序(opposition proceeding)。Computer Motion 先前在其 2002 年 4 月 3 日的新聞稿中宣布,該程序的一項初步裁定對其有利。這個說法已不再正確。7 月 2 日,歐洲專利局由三位法官組成的合議庭將異議程序中的實體爭點延後審理,待提交進一步書面陳述後再行考量,因而使先前的初步決定失去效力。

  • In addition, because the three-judge panel found that this postponement was necessitated by Computer Motion?s abuse of process the Patent Office ordered Computer Motion to pay Intuitive?s costs including our attorney fees. We do not expect another hearing in the EPO on this matter until some time in early 2003.

    此外,由於三位法官的合議庭認定此次延後係因 Computer Motion 濫用程序(abuse of process)所致,專利局命令 Computer Motion 支付 Intuitive 的費用,包括我們的律師費。我們預期 EPO 就此事不會在 2003 年初之前再舉行聽證。

  • That completes the legal summary, and now I?ll pass the floor back to Lonnie.

    以上為法律摘要,接下來我把時間交回給 Lonnie。

  • Lonnie Smith

    Lonnie Smith

  • That completes our presentation, and we will now open the call to questions.

    以上完成我們的簡報,現在開放提問。

  • Operator

    Operator

  • Thank you. (Caller Instructions.)

    謝謝。(來電者指示。)

  • Charles Olsziewski from UBS Warburg.

    UBS Warburg 的 Charles Olsziewski。

  • Charles Olsziewski - Analyst

    Charles Olsziewski - Analyst

  • Well, there?s certainly a lot of speakers on this call, but I?m sure David is going to be the most popular. And that?s not a knock on anyone else. But let me start, David, with you. My ? obviously, in the press release that came out today that the Court clearly concluded that infringement exists. But in listening to your other comments, did Computer Motion, in fact, try to show that this patent was also invalid or unenforceable? And my question is if I did hear you correctly, and they did under certain, did somehow try to do that, if they have to go to Court to try and do that, what other path would they have if they were, in fact, denied those motions, if that?s what they?re called? In the initial phase of this whole process?

    嗯,這通電話的講者確實很多,但我敢肯定 David 會是最受歡迎的。這並不是在貶低其他任何人。不過 David,我先從你開始。我——顯然,今天發布的新聞稿中,法院明確認定存在侵權。但聽你其他評論時,Computer Motion 是否確實也試圖主張該專利無效或不可執行?我的問題是:如果我沒聽錯,而且他們確實在某些方面試圖這麼做,那麼如果他們的那些動議(如果是這樣稱呼的話)被駁回,他們若要再主張無效或不可執行,除了上法院之外,還有什麼其他途徑?在整個流程的初期階段?

  • David Shaw

    David Shaw

  • Hi, Charles. Let me say ?

    嗨,Charles。我先說——

  • Charles Olsziewski - Analyst

    Charles Olsziewski - Analyst

  • That wasn?t a very clear question. I understand that, but.

    這不是一個很清楚的問題。我理解,但——

  • David Shaw

    David Shaw

  • I think I know where you?re going with it, so let me try it this way. The summary judgment process was a means by which Computer Motion attempted to avoid trial.

    我想我知道你要問的方向,所以我換個方式回答。簡易判決程序是 Computer Motion 試圖避免進入審判的一種手段。

  • Charles Olsziewski - Analyst

    Charles Olsziewski - Analyst

  • Okay.

    好的。

  • David Shaw

    David Shaw

  • If a summary judgment motion is filed and it is granted by the defendant then trial won?t be necessary. They win as a matter of law based on the facts presented to the Court. The Court ruled, actually the Court denied all four of Computer Motion?s attempts to avoid trial.

    如果提出簡易判決動議,且被告的動議獲准,那麼就不需要審判了。他們會依據提交給法院的事實,在法律層面上勝訴。法院裁定——其實法院駁回了 Computer Motion 為了避免審判所做的四次嘗試。

  • Charles Olsziewski - Analyst

    Charles Olsziewski - Analyst

  • Okay.

    好的。

  • David Shaw

    David Shaw

  • They basically said, you know what, you presented your arguments to me, you?ve presented the facts, and I cannot grant you the relief you request. And so now we need trial. Computer Motion, the trial, since infringement is already proven, the judgment is already entered, we now don?t carry a burden of proof on that. The jury will be instructed that they infringe.

    他們基本上是說,你知道的,你把你的論點都呈給我了,你也提出了事實,而我無法給你所要求的救濟。因此現在我們需要進入審判。至於 Computer Motion 的審判,由於侵權已經被證明、判決也已經作成,我們在這一點上不再負有舉證責任。陪審團將被告知他們構成侵權。

  • The issue now is whether Computer Motion can prove by a certain amount of evidence called ?clear and convincing? that the patent is invalid before the jury, and they can try arguing ?enablement? once again. They can try arguing ?best mode? once again. They may try other defenses, and obviously, there will be a jury verdict on those kinds of issues.

    目前的爭點是,Computer Motion 是否能在陪審團面前,以一種稱為「明確且令人信服」(clear and convincing)的證據程度,證明該專利無效;他們也可以再次主張「可實施性」(enablement)。他們可以再次主張「最佳模式」(best mode)。他們也可能提出其他抗辯,而顯然,陪審團將就這類爭點作出裁決。

  • The denial of these motions, however, was very important to us because if we?d not succeeded in defeating all of our motions we wouldn?t have a right to go to trial, and now we do. And now we get a right to tell the jury why we should prevail. And the damage that we have incurred as a result of that infringement. And that was what they were trying to avoid. Does that answer your question?

    然而,這些動議被駁回對我們非常重要,因為如果我們未能成功擊敗所有這些動議,我們就沒有權利進入審判,而現在我們有了。而現在我們有權向陪審團說明為何我們應該勝訴。以及我們因該侵權所遭受的損害。而那正是他們試圖避免的。這有回答你的問題嗎?

  • Charles Olsziewski - Analyst

    Charles Olsziewski - Analyst

  • Yes, but I guess what I was ? where, to take it step further, they tried to establish invalidity or unenforceability on this, enabling or best mode path, if you will?

    有,但我想我是在問——再往下追問一步,他們是試圖透過這條路徑來主張無效或不可執行性,也就是你說的可實施性或最佳模式這條路徑?

  • David Shaw

    David Shaw

  • Yes.

    是的。

  • Charles Olsziewski - Analyst

    Charles Olsziewski - Analyst

  • Are those the most common ways to try and establish that? And if the Court actually denied those motions why would they attempt to use that same type of approach in trial? Wouldn?t it probably not work there as well?

    那些是最常見用來主張的方式嗎?而如果法院其實已經駁回了那些動議,他們為什麼還會在審判中嘗試用同樣的方式?那不是很可能在那裡也行不通嗎?

  • David Shaw

    David Shaw

  • I, out of Intuitive and Computer Motion, Computer Motion is probably better able to answer that question.

    在 Intuitive 和 Computer Motion 之間,Computer Motion 可能更能回答這個問題。

  • Charles Olsziewski - Analyst

    Charles Olsziewski - Analyst

  • Okay.

    好的。

  • David Shaw

    David Shaw

  • They certainly have a right to continue to mount those defenses at trial if they so choose. Whether they will choose to do so remains unclear.

    如果他們選擇這麼做,他們當然有權在審判中繼續提出那些抗辯。他們是否會選擇這麼做,目前仍不清楚。

  • Charles Olsziewski - Analyst

    Charles Olsziewski - Analyst

  • Okay, and one final question. And this may be a question more for Lonnie. But ? or certainly you, too, David. But I mean this ruling, obviously, gives you pretty bullish feeling about this case as it is initially unfolding. But I would assume that when you talk about damages, since Computer Motion has limited financial resources, the more important part of this is, in fact, the tremendous leverage it might give you in the other litigation that?s ongoing. Is that part of the strategy here? Do you have any comments on that?

    好的,最後一個問題。這可能更適合問 Lonnie。但——或者你也可以回答,David。不過我的意思是,這項裁定顯然讓你們對這個案件在初期發展上感到相當樂觀。但我想,當你談到損害賠償時,由於 Computer Motion 的財務資源有限,這件事更重要的部分其實是,它可能在另一個仍在進行的訴訟中給你們帶來巨大的談判籌碼。這是這裡策略的一部分嗎?你們對此有任何評論嗎?

  • Lonnie Smith

    Lonnie Smith

  • I don?t think it would be appropriate for us to comment on that at this point in time, Charles.

    Charles,我認為我們在此時此刻不適合對此發表評論。

  • Charles Olsziewski - Analyst

    Charles Olsziewski - Analyst

  • Okay, and my last question, David, is what?s a prosecution latch?

    好的,我最後一個問題,David,什麼是 prosecution latch?

  • David Shaw

    David Shaw

  • What is a prosecution ?

    什麼是 prosecution?

  • Charles Olsziewski - Analyst

    Charles Olsziewski - Analyst

  • What does that mean?

    那是什麼意思?

  • David Shaw

    David Shaw

  • Prosecution laches is a defense that computer motion has described a number of times. It is an old doctrine that the Federal Circuit appeared to breathe some life back into with a recent decision. [Lemilson v Symbol Technologies.] And essentially, prosecution laches is an age-old doctrine that concerns delay. And prosecution laches turns on a delay in prosecution that is somehow prejudiced the rights of another party due to late claiming of the invention, based on an application that did not originally disclose the invention.

    Prosecution laches(審查遲延抗辯)是 Computer Motion 多次提到的一種抗辯。這是一項古老的法理原則,而聯邦巡迴上訴法院似乎在近期的一項判決中讓它重新獲得一些生命力。[Lemilson v Symbol Technologies.]本質上,prosecution laches 是一項歷史悠久、與延宕有關的法理。

  • Here, we have an application that did disclose the original invention, which is why we believe prosecution laches does not apply in this case. The Court has asked for some further factual discussion. That trial will be held before the judge after the jury phase. The jury doesn?t get [abide] of the prosecution laches defense. And the judge will rule, and will present the legal analysis to point-out why it doesn?t apply in this case. Hopefully, that clears it up a little bit at least.

    在本案中,我們的申請確實揭露了原始發明,這也是為什麼我們認為 prosecution laches 不適用於本案。法院要求就部分事實再作進一步討論。該部分審理將在陪審團階段之後,由法官進行。陪審團不會[abide]審理 prosecution laches 這項抗辯。法官將作出裁定,並提出法律分析,指出為何它不適用於本案。希望這至少能讓你更清楚一些。

  • Charles Olsziewski - Analyst

    Charles Olsziewski - Analyst

  • Okay. I have a couple other questions, but I?ll get back in queue. Thanks.

    好的。我還有幾個問題,但我會回到隊列後面。謝謝。

  • Operator

    Operator

  • Alex [Arrow] from [Latenburg Thalman], you may ask your question.

    接下來是來自 [Latenburg Thalman] 的 Alex [Arrow],你可以提問。

  • Alex Arrow - Analyst

    Alex Arrow - Analyst

  • Thanks. Congratulations on your record-setting quarter.

    謝謝。恭喜你們創下紀錄的一季。

  • My first question is about one of the comments Susan made about the second console being sold to an existing customer. I?m wondering if that is representative of something, a trend that?s going to continue? Why would a customer need two consoles? And should we consider that a consumable? And is that why you put it in your consumables line?

    我的第一個問題是關於 Susan 提到的一點:第二台控制台是賣給既有客戶。我想知道這是否代表某種情況、某個將會持續的趨勢?為什麼客戶會需要兩台控制台?我們應該把它視為耗材嗎?這也是你們把它放在耗材項目裡的原因嗎?

  • Susan Barnes

    Susan Barnes

  • It?s put in accessories and consumables line, and called-out that it is not a recurring revenue pattern. I think it?s unique to a European customer that?s doing simulation research in their lab.

    它被放在配件與耗材項目中,並且特別說明這不是一種經常性收入模式。我認為這是某個歐洲客戶的特殊情況,他們在實驗室進行模擬研究。

  • Alex Arrow - Analyst

    Alex Arrow - Analyst

  • So in other words, it?s two consoles hooked-up to the same robot at the same time. Do they both operate the robot?

    所以換句話說,是兩台控制台同時連接到同一台機器人上。它們兩台都操作那台機器人嗎?

  • Lonnie Smith

    Lonnie Smith

  • They will. This is still in a developmental phase, but ?yes? they would be able longer term to have some control over the robot.

    會的。這仍處於開發階段,但——是的——長期而言,他們將能對機器人有一定程度的控制。

  • Susan Barnes

    Susan Barnes

  • Or they could drive simulation software where there?s no actual patient underneath, that console could.

    或者他們可以操作模擬軟體,在沒有實際病患的情況下,那台控制台也可以。

  • Lonnie Smith

    Lonnie Smith

  • But at this point in time it?s being used as Susan said, for simulation.

    但就目前而言,它如 Susan 所說,是用於模擬。

  • Alex Arrow - Analyst

    Alex Arrow - Analyst

  • OK, so we should just consider the consumables 2.2 million then for this quarter, rather than 2.7?

    好的,那我們本季耗材應該只看 220 萬,而不是 270 萬,對嗎?

  • Susan Barnes

    Susan Barnes

  • No.

    不是。

  • Lonnie Smith

    Lonnie Smith

  • That?s correct.

    那樣說是對的。

  • Susan Barnes

    Susan Barnes

  • You?re right, that is right.

    你說得對,那是對的。

  • Lonnie Smith

    Lonnie Smith

  • And then the consumables portion is 2.2, and then when we said 3.3 in total that included the service piece.

    然後耗材部分是 220 萬,而我們說的總計 330 萬包含了服務的部分。

  • Alex Arrow - Analyst

    Alex Arrow - Analyst

  • Okay, great. Second question, the survey that you did about your customer satisfaction that you got the nine points out of 10 on that study. That sounds great. Can you give us any context to benchmark that? I mean I would imagine that most of those studies come out fairly positive because of the psychology of having bought something. You know, you want to feel good about your purchase. So is there an average result across all different medical devices in those studies that we can compare that to.

    好的,很棒。第二個問題,你們做的客戶滿意度調查,在那份研究中拿到 10 分中的 9 分。聽起來很不錯。你能否提供一些背景,讓我們可以做基準比較?我的意思是,我想多數這類研究結果都會相當正面,因為買了東西會有心理因素。你知道,你會想對自己的購買感覺良好。所以在那些研究中,是否有跨各種醫療器材的平均結果,讓我們可以拿來比較?

  • Lonnie Smith

    Lonnie Smith

  • Well, you know, not that we, not from this study specifically. But from my prior, prior lives we used to benchmark ourselves against other, you know, leading medical companies. And I will tell you that we didn?t hit the nine mark even at, in my prior experience.

    嗯,你知道的,就這份研究本身而言,我們沒有那樣的比較數據。但在我以前、以前的工作經驗裡,我們會拿自己去和其他、你知道的、領先的醫療公司做基準比較。我可以告訴你的是,即使在我過去的經驗中,我們也沒有達到 9 分這個水準。

  • And so I think that, but I do agree that there?s always, you know, with the recent purchase and a purchase of this size, there are elements as you say where people like, want to feel good about the purchase. This study, that?s just a very top line. The study goes into a lot of detail which we consider to be proprietary information.

    所以我認為——但我也同意,確實總是會有,你知道的,因為是近期購買、而且是這麼大金額的購買,會有你所說的那種因素:人們會想、想要對這次購買感覺良好。這份研究,我們目前分享的只是非常高層次的結果。研究本身包含很多細節,我們認為那是專有資訊。

  • And the purpose of that is, of course, as I said, not to pat ourselves on the back, or not to feel great about it, but to find out how we can better serve them. How do we prioritize our efforts here. And where do we, and really the focus is where do we improve.

    而其目的當然如我所說,不是自我誇獎,也不是為此感到多麼得意,而是要找出我們如何能更好地服務他們。我們要如何在這裡排定工作的優先順序。以及我們要在哪些方面——而真正的重點是我們要在哪裡改進。

  • Alex Arrow - Analyst

    Alex Arrow - Analyst

  • Okay, and thanks. And then my last question, and I?ll get back in queue, is for us to project your legal expenses going forward, I?m wondering if you can tell us what your relative inclination is to continue to fight to the end with Computer Motion versus the idea of settling at some point? They?ve said publicly that they are ready to talk about a settlement, and I don?t think you?ve ever made any statement to that effect. But you?re, if you feel so inclined to comment now about your relative appetite for settlement, that will help us project your legal expenses.

    好的,謝謝。然後我最後一個問題,我會回到隊列後面:為了讓我們預估你們未來的法律費用,我想知道你們相對上更傾向於和 Computer Motion 一路打到底,還是有可能在某個時間點和解?他們公開表示已準備好談和解,而我不認為你們曾就此發表過任何聲明。但如果你們現在願意評論一下你們對和解的相對意願,將有助於我們預估你們的法律費用。

  • Lonnie Smith

    Lonnie Smith

  • Well, I think that settlement requires both parties, and it?s a two-way street. And you know, we are certainly interested in settling if the terms are appropriate.

    嗯,我認為和解需要雙方配合,這是一條雙向道路。而且你也知道,如果條件合適,我們當然有興趣達成和解。

  • Alex Arrow - Analyst

    Alex Arrow - Analyst

  • Okay, that?s fair enough. I?ll go back in queue, thanks.

    好的,這很公平。我會回到隊列裡,謝謝。

  • Operator

    Operator

  • Rick Wise from Bear Stearns, you may ask your question.

    來自 Bear Stearns 的 Rick Wise,你可以提問。

  • Rick Wise

    Rick Wise

  • Good afternoon, everybody.

    各位下午好。

  • Lonnie Smith

    Lonnie Smith

  • Hi, Rick.

    嗨,Rick。

  • Rick Wise

    Rick Wise

  • A couple of things. First, the Delaware trial, just how long do you think it?s going to last? And you know, and just reflect on the possible outcomes, and how you would proceed to be on there? Is it a short trial? Is it a long trial?

    有幾件事。第一,特拉華州的審判,你認為大概會持續多久?另外,請你談談可能的結果,以及你們接下來會如何應對?這會是一個短的審判嗎?還是一個長的審判?

  • David Shaw

    David Shaw

  • It?s a two-week trial, Rick.

    Rick,這是一個為期兩週的審判。

  • Rick Wise

    Rick Wise

  • And just help us understand. Assuming if you win, what?s the next step beyond that? What are the options?

    再幫我們理解一下。假設你們勝訴,接下來的下一步是什麼?有哪些選項?

  • David Shaw

    David Shaw

  • Well, if we win there could be an appeal of whatever we win. I?m stuttering a little bit, because I?m not sure ?

    嗯,如果我們勝訴,對方可能會就我們勝訴的部分提出上訴。我有點結巴,因為我不確定——

  • Rick Wise

    Rick Wise

  • Well, I?m just trying to understand, you know, it?s like just trying to understand the consequences of, you know, let?s hope you win. Then there?s likely the appeal. Just trying to figure-out how long this is likely to go on, assuming that Computer Motion persists to the end?

    我只是想了解,你知道,就是想了解其後果;希望你們能贏。那接下來很可能會有上訴。我只是想弄清楚,如果 Computer Motion 一路堅持打到底,這件事大概會拖多久?

  • 00:3628 David Shaw: Okay. It likely won?t ? well, the Delaware litigation, at least in the District Court phase, likely won?t proceed much longer. There will be a trial before the jury on whether Computer Motion can prove, you know, by the requisite level of evidence that the patent is somehow invalid. There will be a quick trial after that on its prosecution laches defense, on whatever it would like to say about prosecution laches. After that, there will be some post-trial motions regardless of how things turn-out, there will inevitably be post-trial motions. And after the judge decides those motions then there will be the opportunity for an appeal phase.

    00:3628 David Shaw:好的。很可能不會——嗯,特拉華州的訴訟,至少在地方法院階段,可能不會再拖太久。接下來會在陪審團面前進行審理,判斷 Computer Motion 是否能以所要求的證據標準證明該專利在某種程度上無效。之後會就其「prosecution laches(審查遲延)」抗辯進行一個快速審理,針對它想就 prosecution laches 提出的任何主張。再之後,無論結果如何,都會有一些審後動議;不管事情怎麼發展,審後動議幾乎不可避免。而在法官裁定這些動議之後,就會進入可提出上訴的階段。

  • Rick Wise

    Rick Wise

  • Okay. Jumping around a little bit. Susan, your comfort with the second half outlook in terms of ? you talked about the third quarter. We?re assuming 22 units in the fourth quarter, 22 instruments. Does that still sound like a reasonable place to be to you?

    好的。我稍微跳一下話題。Susan,關於下半年展望你的把握程度——你談到了第三季。我們假設第四季是 22 台、22 套儀器。這對你來說仍然是合理的水準嗎?

  • Susan Barnes

    Susan Barnes

  • Yeah, we do. We are not changing year guidance. It may be a cut-off issue, but we?re not changing your guidance.

    是的,我們認為是。我們不會調整全年指引。可能會有截止認列的問題,但我們不會改變你們的指引。

  • Rick Wise

    Rick Wise

  • Okay. And can you comment on the, say it as you will, the instruments, the procedures per instrument? Or per system rather, or instruments used per system, or procedures per system, are you seeing consistent growth, let?s say in the second 50 versus the first 50 instruments placed, or if the math is, you know, second 68 versus the first 50? Is, you know, is this quarter, was it skewed more toward the more recently placed? Or was there a higher number in the instruments placed earlier? Can you help us in any way?

    好的。你能否評論一下——怎麼說都行——儀器的使用情況、每台儀器的手術量?或者更準確地說,每套系統的手術量,或每套系統使用的儀器數;你們是否看到一致的成長,例如後 50 台相較於前 50 台已安裝設備,或如果用數學來看是後 68 台相較於前 50 台?也就是說,本季是否更偏向近期新裝機的使用?還是較早期安裝的設備使用量更高?你能否在任何方面幫我們理解?

  • Susan Barnes

    Susan Barnes

  • Right. Yes, we?ve always said this isn?t an exact science and somewhat driven by surgeons and personalities, but I would say this that where we?ve had a chance and an opportunity to train more than one specialty which tends to be in the earlier units versus the brand-new units, we have seen system usage consistently grow with the addition of multi-specialty units. And that?s about as much detail as we want to go into.

    對。是的,我們一直說這不是精確科學,某種程度上取決於外科醫師與個人特質;但我會這麼說:在我們有機會、也有條件訓練不只一個專科的地方——這通常出現在較早期的裝機單位,而不是全新的裝機單位——我們確實看到隨著多專科導入,系統使用量持續成長。我們大概就說到這個程度。

  • Rick Wise

    Rick Wise

  • Okay. And you know, perhaps touch on the impact to the higher average selling price. The reaction you?re getting, and just that?

    好的。另外,你能否談談對較高平均售價的影響?你們收到的反應,以及相關情況?

  • Susan Barnes

    Susan Barnes

  • Other than everyone always asking us to discount which we don?t, that information on how much you sell a system for gets out to the hospitals pretty quick. And we hold on that. And what you?re seeing is the mix with the U.S. Increase in price from the units that were placed on order in the first and second quarter, and we?re executing on those units.

    除了大家總是要求我們打折、但我們不打折之外,系統賣多少錢這種資訊很快就會傳到醫院那邊。而我們會堅持價格。你看到的是美國市場的組合變化。價格上升來自第一季與第二季下單的那些裝機單位,而我們正在交付並執行這些訂單。

  • Rick Wise

    Rick Wise

  • Okay, well, that?s great. Thanks again for a good quarter here.

    好的,這很棒。再次感謝你們交出一個很好的季度成績。

  • Susan Barnes

    Susan Barnes

  • Thank you.

    謝謝。

  • Lonnie Smith

    Lonnie Smith

  • And thank you.

    也謝謝你。

  • Operator

    Operator

  • Charles Olsziewski from UBS Warburg, you may ask your question.

    來自 UBS Warburg 的 Charles Olsziewski,你可以提問。

  • Charles Olsziewski - Analyst

    Charles Olsziewski - Analyst

  • Okay, thanks. Kind of follow-up on more of the fundamental side of the business. You guys have given us a good update on kind of where you are with your clinical programs with mitral valve and ASP, and cavedge, et cetera, and some of the other things that both Fred and Alex talked about.

    好的,謝謝。我想追問一些更偏基本面的問題。你們已經就臨床計畫的進展給了我們很好的更新,例如二尖瓣、ASP、cavedge 等等,以及 Fred 和 Alex 提到的其他一些事項。

  • What, just looking ahead kind of at next generation systems, you know, with the integration potentially of image guided technology, or the integration of procedure simulations for planning and training, and some of the things that may be incorporated into future systems, when should we think, be thinking about kind of the next generation system hitting the market, you know, so from a timing perspective would it cost more for the hospital or less in rough terms, size, et cetera?

    那麼,往前看下一代系統——例如可能整合影像導引技術,或整合用於規劃與訓練的手術模擬,以及未來系統可能納入的一些功能——我們應該何時開始期待下一代系統上市?就時程而言,粗略來說對醫院會更貴還是更便宜、體積大小等等?

  • Lonnie Smith

    Lonnie Smith

  • Charlie, you know, one, we don?t preannounce our development plans or the timing of them. What I will say is that the system is developed, the system is quite modular, and we continue to enhance it. Enhancements will be modular as we, as something allows hospitals to enhance the current system or buy a new system. It deals with both software and hardware, and you know, that?s part of, you know, we consider that to be very proprietary.

    Charlie,你知道,第一,我們不會預先公告我們的研發計畫或其時程。我能說的是,這套系統的設計相當模組化,我們也持續在強化它。未來的強化也會以模組方式推出;在某些條件允許時,醫院可以升級現有系統或購買新系統。這涵蓋軟體與硬體,而你知道,這是——我們認為這些都屬於高度專有的內容。

  • And you know, our job is to make sure that we are constantly increasing the surgical capability to the surgeon, and the economic attractiveness to the hospital. And providing the procedure development that, you know, provides significant benefits to the patients because we believe that this will be largely in the long-term the fuel driving that will be patient demand. But we are not in a position or willing to share our specific developmental plans.

    而且你知道,我們的工作是確保我們持續提升外科醫師的手術能力,以及提升對醫院的經濟吸引力。並推動手術項目開發;我們相信這能為病患帶來顯著效益,因為我們認為長期而言,推動成長的燃料很大程度會是病患需求。但我們目前無法、也不願意分享具體的研發計畫。

  • Charles Olsziewski - Analyst

    Charles Olsziewski - Analyst

  • Okay. And just, Alex, a question for you. You had ticked-off a few new sites that you added in the quarter. William Beaumont, St. Joseph?s Hospital in Atlanta, and you talked about the physician group in Peoria, Illinois. I think there were a few others that I just didn?t get a chance to write down. If you wouldn?t mind ticking those off I?d appreciate it?

    好的。另外,Alex,我有個問題想問你。你剛才列舉了本季新增的幾個新據點。William Beaumont、亞特蘭大的 St. Joseph’s Hospital,還有你提到伊利諾州皮奧里亞的醫師團體。我想還有幾個我來不及記下來。如果你不介意再把那些點名一次,我會很感謝。

  • Alex Arrow - Analyst

    Alex Arrow - Analyst

  • Yeah, well, Charlie, the ones that I mentioned were New York University Hospital, University of Pennsylvania which is also known as [HUP], William Beaumont you mentioned, St. Luke?s, Kansas City, and St. Joseph?s in Atlanta.

    好的,Charlie,我提到的包括:紐約大學醫院(New York University Hospital)、賓夕法尼亞大學(University of Pennsylvania),也就是所謂的 [HUP];你提到的 William Beaumont;堪薩斯市的 St. Luke’s;以及亞特蘭大的 St. Joseph’s。

  • Charles Olsziewski - Analyst

    Charles Olsziewski - Analyst

  • Great, thanks very much.

    太好了,非常感謝。

  • Lonnie Smith

    Lonnie Smith

  • You bet.

    不客氣。

  • Operator

    Operator

  • Brian [Gagnon] from Gagnon Securities. You may ask your question.

    來自 Gagnon Securities 的 Brian [Gagnon]。你可以提問。

  • Neal

    Neal

  • Hi, it?s Neal and Brian. Good afternoon, folks. I?m looking at the deferred revenue line and seeing a small increase, and I?m wondering are you having any success in building a backlog or a pipeline that you can be cementing in your foundation?

    嗨,我是 Neal 和 Brian。各位下午好。我在看遞延收入那一行,看到小幅增加;我想問的是,你們在建立訂單積壓(backlog)或銷售管線(pipeline)方面是否有任何進展,能夠把基礎打得更扎實?

  • Susan Barnes

    Susan Barnes

  • Yes, except when building a backlog in a pipeline, but I don?t think that in this day and age that using the deferred revenue line will give you the same sort of insight. And we are guiding away from that.

    有的,我們確實在建立訂單積壓與管線;但我不認為在現今這個時代,用遞延收入那一行能提供同樣程度的洞見。我們也不建議再用那個指標來解讀。

  • Neal

    Neal

  • So that?s not the indicator, that?s it?

    所以那不是指標,對嗎?

  • Susan Barnes

    Susan Barnes

  • Right.

    對。

  • Neal

    Neal

  • Okay. Can you chat a little bit, or address the pipeline issue? And what are you seeing?

    好的。你能否稍微談談、或回應一下管線的問題?你們看到了什麼?

  • Susan Barnes

    Susan Barnes

  • I think we?re seeing, and it?s evidenced I think in the call by the continued investment of fields that we?re seeing large appetites, we?re seeing continued interest, and we?re seeing growing procedure and momentum out there that is getting out, the word is getting out to more and more communities, hospitals that it?s necessary to have a da Vinci in order to move their surgery programs ahead in a large, you know, a large focus of minimum basis surgery.

    我想我們看到的是——而且我認為從這通電話中我們持續加大前線投入也能看出來——我們看到很大的需求胃口、看到持續的興趣,也看到手術量與動能在外部持續成長;相關口碑正在傳播到越來越多的社區與醫院,他們認為要推進其外科手術計畫、並在微創手術上有更大的布局,就必須配備一台 da Vinci。

  • Neal

    Neal

  • Okay. You mentioned that you were going to increase your field force in the third quarter. Can you give us some idea of what you?re thinking about achieving by say year-end?

    好的。你提到你們打算在第三季增加前線銷售人力。能否讓我們了解一下,你們希望在例如年底前達成什麼目標?

  • Susan Barnes

    Susan Barnes

  • Well, we have said before that in the United States we will go from 10 area sales managers to 20. And we will continue to execute on that plan. And in Europe going from three to five.

    嗯,我們之前說過,在美國我們會把區域銷售經理從10位增加到20位。我們會持續執行這個計畫。而在歐洲則是從3位增加到5位。

  • Lonnie Smith

    Lonnie Smith

  • And then, of course, supporting that are the clinical specialists as well as the service techs.

    當然,支援這些的還包括臨床專員以及服務技術人員。

  • Susan Barnes

    Susan Barnes

  • Right.

    對。

  • Neal

    Neal

  • Right. On legal expenses. I know you don?t want to identify what they are in a quantitative way, but can you give us some direction on kind of what you?ve been spending, and what you think you might spend in the second half?

    對。關於法律費用。我知道你不想用量化方式指出它們是什麼,但你能否給我們一些方向,說明你們大概花了多少,以及你認為下半年可能會花多少?

  • Susan Barnes

    Susan Barnes

  • I think that we have spent a significant amount going into trial, but trial is expensive. And those numbers are imbedded in the guidance we?ve given for the year.

    我認為我們在進入審判前已經花了相當可觀的金額,但審判本來就很昂貴。而這些數字已經包含在我們對全年所提供的財測指引中。

  • Neal

    Neal

  • Yeah, thank you.

    好的,謝謝。

  • Operator

    Operator

  • Alex [Arrow] from Latenburg Thalman, you may ask your question.

    Latenburg Thalman 的 Alex [Arrow],你可以提問。

  • Alex Arrow - Analyst

    Alex Arrow - Analyst

  • Thanks. Just one clinical question. You described three different cardiac trials that are in-progress. The HL septal defect, mitral valves, and cavedge. Is there some point at which you will have general clearance for all cardiac, or are you always going to have to have individual clearances for the different cardiac procedures?

    謝謝。只有一個臨床問題。你描述了三項正在進行中的不同心臟試驗:HL 室間隔缺損、二尖瓣,以及 cavedge。是否在某個時間點你們會取得涵蓋所有心臟適應症的通用核准,還是你們永遠都必須針對不同的心臟手術分別取得個別核准?

  • Susan Barnes

    Susan Barnes

  • That?s a good question, and that?s a dialogue that the company will have in the future with the FDA.

    這是個好問題,而這也是公司未來會與 FDA 進行對話的議題。

  • Lonnie Smith

    Lonnie Smith

  • Well, we certainly hope that we will have general cardiac approval at some point in time. But you know, it?s hard to commit to that until it?s reality.

    嗯,我們當然希望在某個時間點能取得一般性的心臟核准。但你知道,在它成為現實之前,很難對此做出承諾。

  • Alex Arrow - Analyst

    Alex Arrow - Analyst

  • Well, looking at the historical example of what happened in the abdomen did you first have to have gallbladder and then other procedures, and then finally you got general ?

    那麼,從腹部領域過去的歷史例子來看,你們是否先必須取得膽囊,然後其他手術,最後才取得通用的?

  • Lonnie Smith

    Lonnie Smith

  • No, in fact, we agreed to with the agency is that when we got those, those would be representative, an that we would get general laparoscopic approval based upon it. And we have had discussions quite a long time ago, discussed kind of the number of procedures, and the type of procedures it would take to get general cardiac approval. But you know, that is not, there?s nothing, the commitment there, people change at the agency. And positions change. And so we are marching down a path that builds, with approval for several procedures. And then, of course, we would hope to ask for general cardiac approval.

    不,事實上,我們與主管機關的共識是:當我們取得那些核准時,它們將具有代表性,並且我們會以此為基礎取得一般性的腹腔鏡核准。而我們在很久以前就曾討論過,取得一般性心臟核准需要多少項手術、以及需要哪些類型的手術。但你知道,這並不是——那裡沒有任何承諾,主管機關的人員會更替。立場也會改變。因此我們正沿著一條路徑前進:先取得數個手術的核准來逐步累積。然後,當然,我們會希望提出一般性心臟核准的申請。

  • Alex Arrow - Analyst

    Alex Arrow - Analyst

  • Okay, thanks very much.

    好的,非常感謝。

  • Operator

    Operator

  • (Caller Instructions.)

    (來電者指示。)

  • Rick Wise of Bear Stearns, you may ask your question.

    Bear Stearns 的 Rick Wise,你可以提問。

  • Rick Wise, Representative: Hi, it?s actually, she told me to ? just a couple quick follow-ups. First, can you talk about any new product launches in terms of instruments that you?re going to have later this year? And then maybe also address pricing on these instruments? If you?ve been able to pass-through some increases on the actual, the da Vinci, can you pass-through some pricing increases on the instruments, as well.

    Rick Wise,代表:嗨,其實——她叫我——就幾個快速追問。第一,你能談談今年稍晚在器械方面是否會有任何新產品上市嗎?然後也請談一下這些器械的定價?如果你們已經能在實際設備(da Vinci)上轉嫁一些漲價,那麼在器械上也能轉嫁一些價格上調嗎?

  • And then second question, is there any update that you can give us with regard to the da Vinci placement at [J&Js] as a cost facility? Is there anything tangible that?s come out of that, I don?t want to say joint venture, but that placement at that facility? Thanks.

    第二個問題,關於在 [J&Js] 作為成本中心的 da Vinci 裝機,有沒有任何最新進展可以分享?那個設置在該設施的安排,有沒有產生任何具體成果?我不想稱之為合資,但就是那個在該設施的裝機安排。謝謝。

  • Susan Barnes

    Susan Barnes

  • All right, you know, we have talked in the conferences about having a series of instruments including our [atrimatic graspers] and our [tripolar atrimatic graspers] are out, the bipolar is coming. We are very sensitive to the price per procedure, and do not intend to increase that to the medical community at this point in time.

    好的,你知道,我們在研討會上談過,我們會推出一系列器械,包括我們的 [atrimatic graspers] 以及 [tripolar atrimatic graspers] 已經上市,雙極(bipolar)也即將推出。我們對每例手術的成本非常敏感,目前並不打算把這個成本提高轉嫁給醫療界。

  • In terms of the [Epicon] Center, I will let Alex take that one.

    至於 [Epicon] Center,我讓 Alex 來回答。

  • Aleks Cukic

    Aleks Cukic

  • As far as to your question as to anything tangible, I think actually today Epicon will be receiving a second console independent of the one Susan was discussing earlier. And this console is intended to be used by multiple physicians as they are a part of the test drive program on da Vinci at the Epicon Institute. In other words, it will accommodate for the overflow of just, of being able to accommodate for more than one surgeon sitting down and seeing the 3-D visualization, and help manage some of that flow.

    就你問的是否有任何具體成果而言,我想其實就在今天,Epicon 會收到第二個控制台,獨立於 Susan 先前提到的那一個。這個控制台的用途,是讓多位醫師在 Epicon Institute 參與 da Vinci 試駕(test drive)計畫時使用。換句話說,它將用來因應人潮溢出——能讓不只一位外科醫師坐下來觀看 3-D 視覺化,並協助管理部分流程。

  • As far as tangible, we have a number of leads that were written over the quarter, and those leads are funneled back into the general sales organization in which there?s follow-up protocols by the individual sales manager. And we?ve been quite pleased with both the number of test drives, the number of leads, and the number of follow-up activities generated from that system.

    就具體成果而言,我們在本季獲得了多個潛在客戶線索(leads),而這些線索會回流到一般銷售組織,由各區域銷售經理依照既定的跟進流程進行後續。我們對試駕次數、線索數量,以及由該系統所帶動的跟進活動數量都相當滿意。

  • Lonnie Smith

    Lonnie Smith

  • And for the Midwest it?s been a great place to take surgeons for a test drive, and to give them a chance to use the system in a clinical environment.

    而對中西部而言,這一直是帶外科醫師去試駕的好地方,讓他們有機會在臨床環境中使用該系統。

  • Rick Wise, Representative: Okay, great. And then maybe just one final question regarding can you give us some update on your clinical progress for atrial fibrillation? Thanks.

    Rick Wise,代表:好的,很好。最後再問一個問題,關於你們在心房顫動(atrial fibrillation)的臨床進展,能否提供一些更新?謝謝。

  • Susan Barnes

    Susan Barnes

  • We do not have an Intuitive sponsored afib trial going on. There may at some point in time be something a physician would want to sponsor, but we?re not doing a global afib trial at this point in time.

    我們目前沒有進行由 Intuitive 贊助的 afib 試驗。未來某個時間點可能會有醫師想要自行贊助,但我們目前並沒有在做全球性的 afib 試驗。

  • Rick Wise, Representative: But there is some clinical activity going on in afib? Am I right? Or is it just individual physicians doing it?

    Rick Wise,代表:但在 afib 方面確實有一些臨床活動在進行?我說得對嗎?還是只是個別醫師在做?

  • Susan Barnes

    Susan Barnes

  • It is individual physicians doing it.

    是個別醫師在做。

  • Rick Wise, Representative: Okay, great. Thank you.

    Rick Wise,代表:好的,很好。謝謝。

  • Lonnie Smith

    Lonnie Smith

  • Thank you. We have time for one more question.

    謝謝。我們還有時間再接受一個問題。

  • Operator

    Operator

  • Daniel [Zemuth] from [Chilton] Company. You may ask your question.

    來自 [Chilton] Company 的 Daniel [Zemuth]。你可以提問。

  • Daniel Zemuth - Analyst

    Daniel Zemuth - Analyst

  • Thanks very much. Excellent quarter. Good results. Also, just wanted to follow-up, can you provide any information regarding the number of the units in place where there is multi-specialty surgeons qualified to use the device? And then, also can you give some quantification for the date at which doctors are being trained on the device? And how many doctors in total are trained to use the device?

    非常感謝。本季表現很出色。成果很好。另外想追問一下,你能否提供任何資訊,關於目前已裝機的單位中,有多少是具備多專科外科醫師且有資格使用該設備的?另外,你也能否量化醫師接受該設備訓練的速度?以及總共有多少位醫師已受訓可使用該設備?

  • Lonnie Smith

    Lonnie Smith

  • Well, I don?t have off the top of my head, I don?t have the number of centers that are multi-specialty versus single specialty. Our goal in the sales organization is to make every center a multi-specialty site if we can. Some of those sites that?s not possible, where it?s strictly a cardiac center and they have no other specialties.

    嗯,我一時之間沒有——我沒有多專科中心與單一專科中心的數量。我們銷售組織的目標是:如果可以的話,讓每個中心都成為多專科據點。有些據點則不可能,例如它完全是心臟中心,沒有其他專科。

  • What was the second part of the question?

    第二部分的問題是什麼?

  • Daniel Zemuth - Analyst

    Daniel Zemuth - Analyst

  • The total number of doctors that are trained, and the rate at which you?re training doctors?

    受訓醫師的總數,以及你們訓練醫師的速度?

  • Lonnie Smith

    Lonnie Smith

  • Well, right now we?re training at, I?ve forgotten what we?ve done ? what have we done this year? So far this quarter? A hundred? We?re training at a higher rate, you know, in fact, you know most of our training centers are pretty much booked. And you know, this is something we see as kind of transitioning. Especially with some of the approvals to some of these centers will become very procedure specific. You know, we get mitral valve approval, I would expect there will be several centers that will focus heavily on mitral valve training. And I think with the DVP we will start to see some centers specialize on the specifically da Vinci prostectomy surgery.

    嗯,目前我們的訓練速度是——我忘了我們做了——我們今年做了多少?到目前為止這一季?一百位?我們正以更高的速度在訓練;你知道,事實上,我們大多數訓練中心幾乎都已排滿。而你知道,我們認為這會是一種轉型。尤其是隨著某些核准下來,部分中心會變得非常「手術項目特定」。你知道,如果我們取得二尖瓣核准,我預期會有幾個中心會高度聚焦在二尖瓣訓練。而我認為隨著 DVP,我們將開始看到一些中心專注於特定的達文西前列腺切除(da Vinci prostectomy)手術。

  • Susan Barnes

    Susan Barnes

  • Right. The other thing we?re working on, Dan, a bit, is that we don?t want to train without a clinical plan behind it. That just saying you train doctors for the sake of training doctors is not only a number that doesn't mean much, but is an expensive number. So we are working very closely with the sales force that when a doctor is trained, they have a clinical plan, once they?re back at their hospital.

    對。Dan,我們另外也在做的一件事是:我們不希望在沒有臨床計畫支撐的情況下進行訓練。僅僅為了訓練而訓練醫師,不僅是一個意義不大的數字,而且成本也很高。因此我們正與銷售團隊非常緊密合作,確保當一位醫師受訓後,回到其醫院時有一套臨床計畫。

  • Lonnie Smith

    Lonnie Smith

  • Yeah, the key is once they?re trained is for them to immediately begin doing procedures, and do enough that they get down the experience curve aways so that the, you know, so this becomes the way they want to do procedures in the future.

    是的,關鍵在於他們一旦受訓完成,就要立刻開始進行手術操作,並且做得夠多,讓他們很快沿著經驗曲線往下走,這樣一來,你知道,這就會成為他們未來想要採用的手術方式。

  • Daniel Zemuth - Analyst

    Daniel Zemuth - Analyst

  • I see. And then just on the atrial defibrillation, why wouldn?t the company want to be involved in sponsoring the trial?

    我了解。那再談一下心房顫動(atrial defibrillation),為什麼公司不想參與贊助這項試驗呢?

  • Susan Barnes

    Susan Barnes

  • We didn?t say we wouldn?t want to. I think that we have found a pattern on clinical trials. If the surgeon does a feasibility study first, which is what they did with the mitral valve trial, cook the procedure. We go arm in arm to the agency, discuss that procedure, define a clear and definite outcome and execute a multi-center trial against that, that is what we prefer to do. That has worked well with the agency, and it goes back to a previous question on what does it mean to get cardiac approval. That is early stage right now. We have seen lots of ideas floating around, and some activity out there, but not enough. What we feel could be defined as a clear clinical path to work with the FDA on yet. We?re not saying we won?t do it, we?re just not doing it right now.

    我們並沒有說我們不想。我想我們在臨床試驗上看到了一種模式。如果外科醫師先做可行性研究(feasibility study),就像他們在二尖瓣試驗中所做的那樣,把手術流程「煮熟」/打磨成熟。接著我們會與主管機關並肩合作,討論該手術流程,定義清楚且明確的終點,並據此執行一項多中心試驗,這是我們偏好的做法。這種方式與主管機關合作得很順利,也回到先前那個問題:取得心臟適應症核准(cardiac approval)意味著什麼。目前仍處於非常早期的階段。我們看到很多想法在流傳,也有一些活動,但還不夠。就我們的感受而言,還沒有一條足夠清晰的臨床路徑,可以用來與 FDA 合作。我們不是說不會做,只是現在還沒做。

  • Lonnie Smith

    Lonnie Smith

  • The answer is we are very interested in doing so when we think that the instrumentation and the data supports such a study. And you know, as Susan said, this is still a pretty early stage. There?s a lot of people working on afib ablation devices. And you know, we?re looking at those results very carefully, and so are the surgeons. And we anticipate that if the results are good that we will have surgeons that will want to do exactly as Susan says. Know the procedure, to a physician sponsored IDE, and if the results are good then we will take that to the FDA with a proposal for a broader study.

    答案是:當我們認為器械配置與數據足以支持這樣的研究時,我們非常有興趣去做。而且你知道,正如 Susan 所說,這仍然是相當早期的階段。有很多人在研發心房顫動消融(afib ablation)裝置。而你知道,我們正非常仔細地看這些結果,外科醫師也是。我們預期如果結果良好,會有外科醫師想要照 Susan 所說的方式來做。先把手術流程掌握清楚,進行由醫師主導的 IDE(physician sponsored IDE),如果結果良好,我們就會把它帶到 FDA,提出更大規模研究的提案。

  • Daniel Zemuth - Analyst

    Daniel Zemuth - Analyst

  • And just one final question, to stretch-out my last question here. Have there been approvals, or any new devices introduced, you know, [indiscernible] devices, or clips that are perceived to be important in shortening the procedure time? And have surgeons, you know, excited about the opportunity, the potential?

    最後再問一個問題,延伸一下我剛才的問題。是否已經有核准,或有任何新裝置推出,例如你知道,[聽不清] 的裝置,或夾具(clips),被認為對縮短手術時間很重要?外科醫師是否對這個機會、這個潛力感到興奮?

  • Aleks Cukic

    Aleks Cukic

  • Dan, there are a whole slew of companies that are developing an astomatic, or automatic and astomatic coupling devices. So I won?t comment on the individual companies, but I will say that we are working with some of these companies, and you know, we are encouraged that da Vinci will fit into potential, as a potential platform for launching some of these devices in the future. But to say you know, which device, or what we expect, or when we expect it would be sort of premature on our part. So I would just say that we?re very interested in it, we?re looking at it, and stay-tuned.

    Dan,目前有一大堆公司正在開發吻合(anastomotic)或自動、吻合耦合(coupling)裝置。所以我不評論個別公司,但我可以說,我們正在與其中一些公司合作,而且你知道,我們很受鼓舞,da Vinci 未來有機會作為一個平台,用來導入其中一些裝置。但要說你知道,是哪一個裝置、我們預期什麼、或何時預期發生,對我們來說都還太早。所以我只能說,我們非常有興趣,我們正在關注,敬請期待。

  • Daniel Zemuth - Analyst

    Daniel Zemuth - Analyst

  • So this is kind of a long-term thing? These things have to go through a very extensive trial of some sort before they get out in the field? Or would it be something that we would be looking at in the next six to 12 months, when something might be introduced?

    所以這算是比較長期的事情嗎?這些東西在真正投入臨床使用前,必須經過某種非常廣泛的試驗嗎?還是說在接下來 6 到 12 個月內,我們就可能看到有產品推出?

  • Lonnie Smith

    Lonnie Smith

  • Clearly it depends on FDA approval for the devices, and we, as Alex said, and as Fred has said over and over again, is that we believe that with our articulation, the capability of our system we?re well-positioned to support and complement any astomatic devices.

    很明顯這取決於這些裝置是否獲得 FDA 核准;而且如 Alex 所說、也如 Fred 一再強調的,我們相信憑藉我們系統的關節活動度(articulation)與能力,我們具備良好條件去支援並互補任何吻合裝置。

  • But you know, these things, the development processes are long and so are the approval. And you know, there are several that are being used with the system in trials in Europe. And you know, we?ll see. You know, we clearly are supportive of it. We do a lot of work in our lab with these companies, and we?ll continue to do so because we see this as enabling technology. But, you know, we aren?t in the position to call which will be the winners and losers, and which will be FDA approved, and which ones won?t. So.

    但是你知道,這些東西的開發流程很長,核准也是。而且你知道,有幾個正在歐洲的試驗中與本系統一起使用。然後你知道,我們再看看。你知道,我們顯然是支持的。我們在實驗室裡與這些公司做了很多工作,而且會持續做,因為我們把這視為一項賦能技術(enabling technology)。但是,你知道,我們並不處於能夠判斷誰會是贏家或輸家、哪些會獲得 FDA 核准、哪些不會的立場。所以。

  • Daniel Zemuth - Analyst

    Daniel Zemuth - Analyst

  • Have any actually been submitted for approval?

    有任何產品實際上已經送件申請核准了嗎?

  • Lonnie Smith

    Lonnie Smith

  • You know, I can?t comment on it. It depends on the ones that you?re talking about.

    你知道,我無法評論。這取決於你指的是哪些產品。

  • Aleks Cukic

    Aleks Cukic

  • The only one that?s approved for vascular use is [coalescent clip system] which is not a connector, it?s more an alternative to conventional suture. And we have used that in clinical studies in Europe. And is in our FDA protocol. And believe that does fit nicely with the ability to, you know, the system to use devices that are alternative to sutures, and provides an alternative means of putting vessels together. So that one, to my knowledge, is the only FDA approved distal and astomatic device. And then I guess St. Jude?s [proximal] astomatic device is also approved.

    目前唯一獲准用於血管用途的是 [coalescent clip system],它不是連接器(connector),更像是傳統縫線(suture)的替代方案。我們已在歐洲的臨床研究中使用過它。而且它也納入我們的 FDA 試驗方案(protocol)。我們相信它確實很適合,因為該系統能夠使用替代縫線的裝置,並提供另一種把血管接合在一起的方法。所以就我所知,那個是唯一獲 FDA 核准的遠端(distal)吻合裝置。另外我想 St. Jude 的 [proximal] 吻合裝置也已獲准。

  • Daniel Zemuth - Analyst

    Daniel Zemuth - Analyst

  • Great. Thank you so much. Appreciate it.

    太好了。非常感謝。感激不盡。

  • Lonnie Smith

    Lonnie Smith

  • You bet. Thank you.

    不客氣。謝謝你。

  • To close what I would like to do is just review or summarize the quarter. And as we?ve stated, we had a strong financial quarter. Shipped 16 da Vinci Systems, recorded 19.4 in total revenue, up 52 percent from last year?s second quarter. Gross margins were over 52 percent, and we used only 1.2 million in cash, and ended the quarter with over 55 million in cash and cash equivalents. System usage is healthy. We showed solid growth in recurring revenue up to 3.3 million, 82 percent over the prior year, and 17 percent of total revenue. And as Fred mentioned, we?ve completed the mitral valve trial cases, and plan to receive FDA clearance or expect to receive FDA clearance late this year. The [SD] trial is on-track, and we expect that to be early next year, and our cavedge trials are ongoing and we expect clearance sometime late 2003.

    最後我想做的是回顧或總結本季。如我們所述,我們本季財務表現強勁。出貨 16 套 da Vinci 系統,總營收達 19.4(百萬),較去年第二季成長 52%。毛利率超過 52%,我們僅使用 120 萬現金,季末現金及約當現金超過 5,500 萬。系統使用情況健康。經常性收入(recurring revenue)穩健成長至 330 萬,較去年同期成長 82%,占總營收 17%。此外如 Fred 提到,我們已完成二尖瓣試驗病例,並計畫在今年稍晚取得 FDA 核准/預期在今年稍晚取得 FDA 核准。[SD] 試驗進度如期,我們預期在明年初完成;而我們的 cavedge 試驗仍在進行中,預期在 2003 年稍晚某個時間取得核准。

  • That closes the call for the quarter. We look forward to updating you on our progress again in three months. And wish you all a great summer. Thanks for your participation.

    本季電話會議到此結束。我們期待三個月後再次向各位更新我們的進展。祝各位有個美好的夏天。感謝各位的參與。